On March 22, 2022, Syndel’s tricaine methanesulfonate (MS-222) fish anaesthetic Syncaine® received a Marketing Authorization from the United Kingdom’s Veterinary Medicines Directorate (VMD).
Syncaine®, formally known as Tricaine-S and Aqualife TMS, is manufactured at Syndel’s new US production facility. Since its initial US FDA approval in 1997, Syncaine® has become a recognized and highly regarded fish anaesthetic that is widely used in the global aquaculture industry.
Founded in 1972, Syndel is dedicated to delivering fish health solutions for the aquaculture. From Syndel’s head office located in Ferndale, Washington USA, Syndel manufactures and markets a portfolio of products that are specifically dedicated to fish health, nutrition, reproduction, and biosecurity.
